Adesis Announces Joanne Johnson as Vice President of Business Development
January 04 2018 - 4:05PM
Business Wire
Adesis, Inc., a wholly-owned subsidiary of Universal Display
Corporation (Nasdaq:OLED), today announced that Joanne Johnson,
Ph.D. has been appointed Vice President of Business
Development.
“I am delighted to welcome Joanne to the rapidly growing team at
Adesis,” said Andrew Cottone, Ph.D., President of Adesis, Inc.
“Joanne brings a wealth of international experience across various
aspects of the pharmaceutical and biotechnology business arenas.
With her deep technical, marketing and leadership expertise, Joanne
will help enhance our current collaborative relationships, develop
new business opportunities, and expand our partnership engagements.
I am confident that she will be a valuable asset in fostering our
best-in-class customer management and fueling revenue and business
growth for the Company.”
Prior to joining Adesis, Dr. Johnson was Vice President of
Business Development at Asymchem, Inc. During her 9-year tenure,
she gained broad and significant experience in building out global
sales and support teams, and managed significant revenue growth.
Dr. Johnson also brings technical and business-related experience
from AMRI, Biofocus-DPI, the Cancer Research Campaign (CRC) and
Acambis. Dr. Johnson received her Ph.D. from the University of
Wales (UK) and her Bachelor's degree from Durham University (UK).
She completed postdoctoral research at both Southampton and
Cambridge.
“It is an incredibly exciting time to be joining Adesis,” said
Joanne Johnson. “As a leading organic synthesis CRO (contract
research organization) with a rich history of scientific excellence
and the full support of its parent company, Universal Display
Corporation, Adesis is uniquely positioned for its next phase of
growth. To support its bustling customer pipeline, the Company is
expanding its portfolio of discovery, development, and
commercialization services as well as its headcount and footprint.
I am thrilled to be part of the world-class team at Adesis and look
forward to helping broaden its diverse customer base, and grow
through strategic partnerships.”
About Adesis, Inc.
As a wholly-owned subsidiary of Universal Display Corporation,
Adesis, Inc. is a contract research organization (CRO) supporting
the pharma, biotech, catalysis and a number of other industries.
The CRO specializes in organic and organometallic synthesis, in
milligrams to multi-kilogram quantities. Adesis has a business
model of providing clients with organic chemistry services in three
areas: early stage research, scale up and development, and
specialty manufacturing. With over 20 years of success and
approximately 60 chemists with extensive industry and professional
experience, Adesis supports companies in various industries with
small molecule organic chemistry expertise. Adesis provides a range
of services that can supplement research and development efforts.
It can also act as a specialty manufacturer to reinforce supply
chains. To learn more about Adesis, please visit
http://adesisinc.com/.
About Universal Display Corporation
Universal Display Corporation (Nasdaq: OLED) is a leader in
developing and delivering state-of-the-art, organic light emitting
diode (OLED) technologies, materials and services to the display
and lighting industries. To learn more about Universal Display
Corporation, please visit http://www.oled.com.
All statements in this document that are not historical, such as
those relating to the Company’s technologies and potential
applications of those technologies, the Company’s expected results
and future declaration of dividends, as well as the growth of the
OLED and CRO market and the Company’s opportunities in that market,
are forward-looking financial statements within the meaning of the
Private Securities Litigation Reform Act of 1995. You are cautioned
not to place undue reliance on any forward-looking statements in
this document, as they reflect the Company’s current views with
respect to future events and are subject to risks and uncertainties
that could cause actual results to differ materially from those
contemplated. These risks and uncertainties are discussed in
greater detail in Universal Display Corporation’s periodic reports
on Form 10-K and Form 10-Q filed with the Securities and Exchange
Commission, including, in particular, the section entitled “Risk
Factors” in Universal Display Corporation’s annual report on Form
10-K for the year ended December 31, 2016. Universal Display
Corporation disclaims any obligation to update any forward-looking
statement contained in this document.
(OLED-C)
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180104006266/en/
Adesis, Inc./ Universal Display Corporation:Darice Liu,
609-671-0980 x570investor@oled.commedia@oled.com
Universal Display (NASDAQ:OLED)
Historical Stock Chart
From Aug 2024 to Sep 2024
Universal Display (NASDAQ:OLED)
Historical Stock Chart
From Sep 2023 to Sep 2024